Meryx, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.meryxpharma.com
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults with Relapsed/Refractory AML, ALL, or MPAL
Phase 1
Recruiting
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Meryx, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04872478
- Locations
- 🇺🇸
Emory University - WINSHIP Cancer Center, Atlanta, Georgia, United States
🇺🇸Emory University, Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Pharmacokinetic and Safety Study of MRX-2843 in Adults with Relapsed/Refractory Advanced And/or Metastatic Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Advanced CancerMetastatic CancerNeoplasmsNeoplastic ProcessesNeoplasm MetastasisPathologic Processes
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Meryx, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT03510104
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States